The global Chronic Hepatitis B Virus Testing market garnered a market value of US$ 919 Million in 2023 and is expected to accumulate a market value of US$ 1790 Million by registering a CAGR of 6.9% in the forecast period 2023 to 2033. Growth of the Chronic Hepatitis B Virus Testing market can be attributed to technological advancement in diagnostic tools along with increased awareness regarding testing methodologies. The market for Chronic Hepatitis B Virus Testing registered a CAGR of 5.1% in the historical period 2018 to 2022
Chronic Hepatitis B Virus (HBV) testing refers to a series of laboratory tests that detect the presence of the virus in the blood over an extended period. Chronic hepatitis B is a condition in which the HBV infection lasts for more than six months.
Chronic HBV testing typically involves blood tests that detect various markers of the virus, including the hepatitis B surface antigen (HBsAg), the hepatitis B core antibody (anti-HBc), the hepatitis B e antigen (HBeAg), and the hepatitis B surface antibody (anti-HBs). These markers help to determine the stage and severity of the infection, as well as the risk of transmission to others.
Testing for chronic HBV is crucial because it can lead to severe liver damage, including cirrhosis and liver cancer, if left untreated. Early detection of the infection can help to manage the condition and prevent complications. Treatment options for chronic HBV include antiviral medications and regular monitoring of liver function.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 919 Million |
| Anticipated Forecast Value (2033) | US$ 1790 Million |
| Projected Growth Rate (2023 to 2033) | 6.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Chronic Hepatitis B Virus Testing reflected a value of 5.1% during the historical period, 2018 to 2022.
The growth of the market is driven by several factors such as the increasing prevalence of chronic HBV infections, the rising demand for early diagnosis, and the development of advanced diagnostic technologies. The North America region accounted for the largest share of the market, followed by Europe. This was attributed to the high prevalence of chronic HBV infections in countries such as USA and Canada, as well as the availability of advanced diagnostic technologies in developed countries.
Thus, the market for Chronic Hepatitis B Virus Testing is expected to register a CAGR of 6.9% in the forecast period 2023 to 2033.
Rising demand for early diagnosis spurring the demand for testing services
HBV is one of the most common viral infections worldwide, with an estimated 292 million people living with chronic HBV infections. This high prevalence drives the demand for HBV testing and monitoring, as early diagnosis and treatment are crucial to prevent disease progression. Early diagnosis of chronic HBV infection is critical to prevent complications such as cirrhosis and liver cancer. As a result, there is a growing demand for diagnostic tests that can detect the virus in its early stages.
Advances in diagnostic technologies, such as nucleic acid testing (NAT) and point-of-care testing (POCT), have made it easier and faster to detect HBV infections accurately. These technologies have improved the accuracy and sensitivity of HBV testing, leading to more effective diagnosis and treatment.
Governments around the world have launched various initiatives to control the spread of HBV and improve access to testing and treatment. For example, the World Health Organization (WHO) has set a target to eliminate HBV as a public health threat by 2030, which is likely to drive demand for testing.
Public awareness campaigns and education programs have helped to increase awareness about the importance of HBV testing and treatment. As a result, more people are seeking testing for HBV, driving demand for diagnostic tests.
Development of advanced diagnostic technologies bolstering demand for Chronic Hepatitis B Virus Testing Market
Hepatitis B surface antigen (HBsAg) test: This test detects the presence of the HBV surface antigen in the blood, which indicates an active HBV infection.
Hepatitis B core antibody (anti-HBc) test: This test detects the presence of antibodies to the HBV core antigen, which indicates a previous or ongoing HBV infection.
Hepatitis B surface antibody (anti-HBs) test: This test detects the presence of antibodies to the HBV surface antigen, which indicates immunity to HBV or successful vaccination against HBV.
Hepatitis B e antigen (HBeAg) test: This test detects the presence of the HBeAg protein, which indicates active viral replication and a higher risk of transmitting the virus to others.
Hepatitis B viral load test: This test measures the amount of HBV DNA in the blood, which can help to monitor the progression of the infection and the effectiveness of treatment.
Liver function tests: These tests measure levels of enzymes and proteins in the blood that are produced by the liver, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which can indicate liver damage or disease.
Principal Consultant
Limited access to testing in developing countries along with high cost of testing affecting market growth
Access to testing for chronic HBV infections can be limited in developing countries due to factors such as a lack of healthcare infrastructure, limited resources, and poor public awareness of the disease. The cost of diagnostic tests for chronic HBV infections can be high, which may limit access for some patients, particularly those without adequate insurance coverage.
The accuracy of diagnostic tests for chronic HBV infections can vary, leading to false-positive or false-negative results. This can lead to delays in diagnosis and treatment or unnecessary treatment and monitoring. Stigma and discrimination surrounding HBV infection can deter some patients from seeking testing and treatment, particularly in certain cultures where there may be a strong association between the disease and social stigma.
Many people are unaware of the risk factors for HBV infection and the importance of testing and treatment. This can lead to a lack of demand for testing and lower rates of diagnosis and treatment. While there are treatments available for chronic HBV infection, they may not be effective for all patients and can have significant side effects. This can make it difficult to manage the disease and may limit the effectiveness of testing in some cases.
Presence of established healthcare infrastructure propelling market growth in North America
The market growth in North America is driven by factors such as the high prevalence of chronic HBV infection in the region, increasing awareness about the importance of early diagnosis and treatment, and the availability of advanced diagnostic technologies. Additionally, the presence of established healthcare infrastructure and favorable government initiatives to control the spread of HBV have contributed to the growth of the market.
Factors such as a large patient population and a strong focus on research and development in the healthcare industry are contributing to the growth of the market. However, the market in Canada is also expected to grow at a significant rate, driven by factors such as increasing public awareness and government initiatives to improve access to testing and treatment.
Overall, the North America Chronic Hepatitis B Virus Testing Market is expected to continue to grow in the coming years, driven by factors such as increasing demand for accurate and reliable diagnostic tests and a growing focus on disease prevention and management in the healthcare industry. Thus, North America is expected to possess 44% market share for Chronic Hepatitis B Virus Testing Market in 2023.
Increasing number of people undergoing HBV testing boosting market growth
Factors such as increasing demand for accurate and reliable diagnostic tests and a growing focus on disease prevention and management in the healthcare industry is driving the growth of the market in Europe. The market is also expected to grow at a significant rate, driven by factors such as increasing public awareness and government initiatives to improve access to testing and treatment. In addition, the European governments are focusing on developing programs for early detection and treatment of hepatitis B virus infection. This has led to an increase in the number of people undergoing HBV testing, which is driving the growth of the market.
There have been significant advancements in the development of testing technologies for HBV, such as point-of-care tests and nucleic acid testing. This has made testing more accessible and affordable, which has contributed to the growth of the market. Overall, the Europe Chronic Hepatitis B Virus Testing Market is expected to continue to grow in the coming years. Thus, Europe is expected to possess 39% market share for Chronic Hepatitis B Virus Testing Market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Reliable results maximizing use of EIA kits for testing Chronic Hepatitis B Virus Testing
Enzyme Immunoassay (EIA) kits are widely used for Chronic Hepatitis B Virus (HBV) Testing, and they are considered to be a reliable and accurate option for detecting HBV infection. EIA kits are laboratory-based tests that detect specific antibodies or antigens to HBV in a patient's blood sample.
EIA kits are highly sensitive and specific, meaning that they can accurately detect the presence of HBV in a patient's blood with a low rate of false-positive or false-negative results. They are also easy to use and can provide results within a short period of time, typically within a few hours. Thus, EIA kits are expected to hold 53% market share for Chronic Hepatitis B Virus Testing Market in 2023.
Key players in the Chronic Hepatitis B Virus Testing market are Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., Abbott Laboratories, Meridian Bioscience
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 919 Million |
| Market Value in 2033 | US$ 1790 Million |
| Growth Rate | CAGR of 6.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is estimated to reach US$ 1,790 million by 2033.
The presence of established healthcare infrastructure propels market growth.
Limited access to testing in developing countries restrains market growth.
Rising demand for early diagnosis spurs the demand for testing services.
North America holds a substantial share of the market.
1. Executive Summary | Chronic Hepatitis B Virus Testing Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033 5.3.1. Enzyme Immunoassay Kits 5.3.1.1. Hepatitis B Surface Antigen Test 5.3.1.2. Anti-Hepatitis B Surface Antibody Test 5.3.1.3. Anti-Hepatitis B Core Antibody Test 5.3.2. Point-of-Care Testing Kits 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, ByEnd User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis ByEnd User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast ByEnd User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Diagnostic Centres 6.3.4. Home Care 6.4. Y-o-Y Growth Trend Analysis ByEnd User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis ByEnd User, 2023 to 2033 7. Global Market Anayslis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. U.S. 8.2.1.2. Canada 8.2.2. By Product Type 8.2.3. ByEnd User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product Type 8.3.3. ByEnd User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product Type 9.2.3. ByEnd User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. ByEnd User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. U.K. 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Product Type 10.2.3. ByEnd User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. ByEnd User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Product Type 11.2.3. ByEnd User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. ByEnd User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Product Type 12.2.3. ByEnd User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. ByEnd User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Product Type 13.2.3. ByEnd User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. ByEnd User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Product Type 14.2.3. ByEnd User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. ByEnd User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Product Type 15.1.2.2. ByEnd User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Product Type 15.2.2.2. ByEnd User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Product Type 15.3.2.2. ByEnd User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Product Type 15.4.2.2. ByEnd User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Product Type 15.5.2.2. ByEnd User 15.6. U.K. 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Product Type 15.6.2.2. ByEnd User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Product Type 15.7.2.2. ByEnd User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Product Type 15.8.2.2. ByEnd User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Product Type 15.9.2.2. ByEnd User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Product Type 15.10.2.2. ByEnd User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Product Type 15.11.2.2. ByEnd User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Product Type 15.12.2.2. ByEnd User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Product Type 15.13.2.2. ByEnd User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Product Type 15.14.2.2. ByEnd User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Product Type 15.15.2.2. ByEnd User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Product Type 15.16.2.2. ByEnd User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Product Type 15.17.2.2. ByEnd User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Product Type 15.18.2.2. ByEnd User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Product Type 15.19.2.2. ByEnd User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Product Type 15.20.2.2. ByEnd User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Product Type 15.21.2.2. ByEnd User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product Type 16.3.3. ByEnd User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Gilead Sciences 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. GlaxoSmithKline 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Ionis Pharma 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Janssen Sciences Ireland 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Assembly Biosciences 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Janssen and Arrowhead Pharmaceuticals 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Roche 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Vir Biotechnology 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Bio-Rad Laboratories, Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. DiaSorin S.p.A. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Abbott Laboratories 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Meridian Bioscience 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Chronic Hepatitis B Virus Testing Market
